Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Sci. STKE, 30 October 2001
Vol. 2001, Issue 106, p. tw398
[DOI: 10.1126/stke.2001.106.tw398]


Diabetes Anti-diabetogenic and Slimming, Too

Thiazolidinedione ligands of the peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) are used in the clinic to treat type 2 diabetes; however, these agents are not without unwanted side effects. A new ligand N-(9-fluorenylmethyloxycarbonyl)-L-leucine (FMOC-L-Leu) appears to overcome some of these side effects. FMOC-L-Leu activated PPAR{gamma} trascriptional activity. Analysis of the ligand and receptor interaction showed that two FMOC-L-Leu molecules bind to a single receptor and that the conformation of the receptor is altered when bound. FMOC-L-Leu promoted the interaction of PPAR{gamma} with the cofactors p300 and SRC-1, but not with TIF2. Its interaction with TIF2 is preferentially stimulated by a thiazolidinedione compound, rosiglitazone. In terms of stimulating adipocyte differentiation, FMOC-L-Leu was less potent than rosiglitazone both in cultured cells and in mice. However, in two different in vivo insulin sensitivity tests, FMOC-L-Leu enhanced glucose clearance in normal mice, whereas rosiglitazone did not. In mouse models of type 2 diabetes, the diet-induced insulin-resistant mouse and db/db mice, FMOC-L-Leu improved glucose homeostasis without promoting the weight gain seen in the rosiglitazone-treated animals. Thus, FMOC-L-Leu and drugs with similar chemical structure may be new pharmacological tools in the arsenal against type 2 diabetes.

S. Rocchi, F. Picard, J. Vamecq, L. Gelman, N. Potier, D. Zeyer, L. Dubuquoy, P. Bac, M.-F. Champy, K. D. Plunket, L. M. Leesnitzer, S. G. Blanchard, P. Desreumaux, D. Moras, J.-P. Renaud, J. Auwerx, A unique PPAR{gamma} ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol. Cell 8, 737-747 (2001). [Online Journal]

Citation: Anti-diabetogenic and Slimming, Too. Sci. STKE 2001, tw398 (2001).

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882